Long‐term observation of the frequency of secondary colorectal cancer and other malignancies in tyrosine kinase inhibitor treated chronic myeloid leukemia patients and controls
Nina Winkelmann,
Michaela Schwarz,
Bert Hildebrandt,
Oliver Henke,
Lars Bullinger,
Il‐Kang Na,
Sebastian Stintzing,
Philipp le Coutre
Affiliations
Nina Winkelmann
Department of Hematology, Oncology, and Cancer Immunology, Campus Charité Mitte Charité‐Universitätsmedizin Berlin Berlin Germany
Michaela Schwarz
Department of Hematology, Oncology, and Cancer Immunology, Campus Virchow‐Klinikum Charité‐ Universitätsmedizin Berlin Berlin Germany
Bert Hildebrandt
Department of Hematology, Oncology, and Cancer Immunology, Campus Charité Mitte Charité‐Universitätsmedizin Berlin Berlin Germany
Oliver Henke
Department of Hematology, Oncology, and Cancer Immunology, Campus Charité Mitte Charité‐Universitätsmedizin Berlin Berlin Germany
Lars Bullinger
Department of Hematology, Oncology, and Cancer Immunology, Campus Virchow‐Klinikum Charité‐ Universitätsmedizin Berlin Berlin Germany
Il‐Kang Na
Department of Hematology, Oncology, and Cancer Immunology, Campus Virchow‐Klinikum Charité‐ Universitätsmedizin Berlin Berlin Germany
Sebastian Stintzing
Department of Hematology, Oncology, and Cancer Immunology, Campus Charité Mitte Charité‐Universitätsmedizin Berlin Berlin Germany
Philipp le Coutre
Department of Hematology, Oncology, and Cancer Immunology, Campus Charité Mitte Charité‐Universitätsmedizin Berlin Berlin Germany
Abstract In this analysis, we examined the risk of secondary malignancies for tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia (CML) patients. We also collected data on specific risk factors for colorectal cancer. Ninety‐one patients with CML and 76 controls were included and in total 4 (4.4%) secondary malignancies were found in patients and 8 (10.5%) in controls. The risk for secondary malignancies was not significantly elevated for CML patients (p = 0.141). Two (2.2%) CML patients developed colorectal cancer compared to 4 (5.3%) in the reference group. A higher risk for CML patients for colorectal cancer could not be found (p = 0.414).
